J&J Makes Its Biggest Bet Yet On Antibody-Drug Conjugates With Ambrx Buyout

 
• By Alaric DeArment
  
J&J CEO Joaquin Duato spoke about the company's acquisition of Ambrx at the J.P. Morgan Healthcare Conference • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business